Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 46, Issue 4, pp 521–527 | Cite as

Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients

  • Bruria Hirsh Raccah
  • Amihai Rottenstreich
  • Netanel Zacks
  • Mordechai Muszkat
  • Ilan Matok
  • Amichai Perlman
  • Yosef Kalish
Article

Abstract

Data are limited on the effects of drug interactions on direct-acting oral anticoagulant (DOAC) levels. We evaluated the effects of the use of interacting drugs on DOAC levels in patients with atrial fibrillation (AF). We reviewed data of AF patients tested for DOAC levels in 2013–2017. The primary outcomes were drug levels exceeding the expected steady-state range, and in the highest quartile. A multivariate analysis was performed to evaluate the correlation of treatment by the use of interacting drugs, CYP3A4 and P-glycoprotein (P-gp) inhibitors, with the primary outcomes. Overall, 147 patients underwent DOAC level measurement [dabigatran (n = 31), rivaroxaban (n = 29), apixaban (n = 87)]. Thirty-three (22.4%) had drug levels exceeding the expected range. Seventy-nine (53.7%) patients were treated with at least one interacting drug. In multivariate analysis, the concomitant use of interacting drugs was an independent predictor for drug levels exceeding the expected range (OR 3.3, 95% CI 1.20–9.05). The defined daily dose of the interacting drug correlated positively with DOAC levels (r = 0.29, P = 0.001). Co-treatment with interacting drugs was associated with extremely high levels of dabigatran, (OR 16.6, 95% CI 1.29–215.18) but not of the other DOAC examined. Concomitant use of interacting drugs is associated with high DOAC levels in patients with AF. Further investigation is warranted to establish the differences between specific DOAC, evaluate the effect on patient outcomes, and characterize the role of DOAC monitoring in this setting.

Keywords

Drug interaction Direct-acting oral anticoagulants Drug levels CYP3A4 inhibitors P-gp inhibitors 

Notes

Acknowledgements

We appreciate Ms. Cindy Cohen’s help in editing.

Author contributions

BHR contributed to conception, design, acquisition, analysis, and interpretation. AR contributed to conception, design, acquisition and interpretation. NZ contributed to design and analysis. MM contributed to conception and interpretation. IM contributed to design and analysis. AP contributed to design, analysis, and interpretation. YK contributed to conception, design and interpretation. All authors critically revised manuscript and gave final approval.

Compliance with ethical standards

Conflict of interest

The authors do not have any conflicts of interest to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the local institutional review board of Hadassah Medical Center Helsinki Committee.

Informed consent

Informed consent was waived by the by the institutional review board of Hadassah Medical Center.

Supplementary material

11239_2018_1738_MOESM1_ESM.docx (27 kb)
Supplementary material 1 (DOCX 27 KB)

References

  1. 1.
    Douros A, Renoux C, Coulombe J et al (2017) Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. Pharmacoepidemiol Drug Saf 26:1546–1554CrossRefPubMedGoogle Scholar
  2. 2.
    Giustozzi M, Cristina M, Verdecchia P et al (2016) Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. Eur J Intern Med 33:42–46CrossRefPubMedGoogle Scholar
  3. 3.
    Huisman MV, Rothman KJ, Paquette M et al (2017) The changing landscape for stroke prevention in AF. J Am Coll Cardiol 69:777–785.  https://doi.org/10.1016/j.jacc.2016.11.061 CrossRefPubMedGoogle Scholar
  4. 4.
    Steffel J, Verhamme P, Potpara TS et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRefPubMedGoogle Scholar
  5. 5.
    Wessler JD, Hil MP, Grip LT et al (2013) The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 61:2495–2502CrossRefPubMedGoogle Scholar
  6. 6.
    Hellwig T, Gulseth M (2013) Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation ? Ann Pharmacother 47:1478–1487CrossRefPubMedGoogle Scholar
  7. 7.
    Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651CrossRefPubMedGoogle Scholar
  8. 8.
    Frost CE, Byon W, Song Y et al (2014) Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 79:838–846CrossRefGoogle Scholar
  9. 9.
    Mueck W, Kubitza D, Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76:455–466CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T (2000) Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 55:843–852CrossRefPubMedGoogle Scholar
  11. 11.
    Nishio S, Watanabe H, Kosuge K et al (2005) Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 28:223–227CrossRefPubMedGoogle Scholar
  12. 12.
    Katoh M, Nakajima M, Yamazaki H et al (2000) Inhibitory potencies of antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 17:1–9CrossRefGoogle Scholar
  13. 13.
    Drug Safety and Availability, FDA Drug Safety Communication, New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. https://www.fda.gov/Drugs/DrugSafety/ucm256581.htm
  14. 14.
    Drug Development and Drug Interactions (2018) Table of substrates, inhibitors and inducers, pp 1–14. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2
  15. 15.
    Eikelboom JW, Quinlan DJ, Hirsh J et al (2017) Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol 2:566–574CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Apixaban, highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
  18. 18.
  19. 19.
  20. 20.
    Rottenstreich A, Zacks N, Kleinstern G et al (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 45:543–549CrossRefPubMedGoogle Scholar
  21. 21.
    Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  22. 22.
    Patel MR, Mahaffey KW, Garg J et al (2010) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:609–619Google Scholar
  23. 23.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  24. 24.
    Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefPubMedGoogle Scholar
  25. 25.
    Center for Drug Evaluation and Research Application Number, 202439Orig1s000, medical review, rivaroxaban. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202439Orig1s000MedR.pdf
  26. 26.
    Center for Drug Evaluation and Research Application Number, 202155Orig1s000, medical review, apixaban. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000MedR.pdf
  27. 27.
    Center for Drug Evaluation and Research Application Number: 22-512, medical review, dabigatran. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000MedR.pdf
  28. 28.
    Chang S-H, Chou I-J, Yeh Y-H et al (2017) Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 318:1250–1259CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ruff CT, Giugliano RP, Braunwald E et al (2015) Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 6:2288–2295CrossRefGoogle Scholar
  30. 30.
    Reilly PA, Lehr T, Haertter S et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol 63:321–328CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of CardiologyHadassah University HospitalJerusalemIsrael
  2. 2.Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of MedicineHebrew University of JerusalemJerusalemIsrael
  3. 3.Department of HematologyHadassah-Hebrew University Medical CenterJerusalemIsrael
  4. 4.Division of Clinical Pharmacology, Department of MedicineHadassah University HospitalJerusalemIsrael
  5. 5.Department of MedicineHadassah University HospitalJerusalemIsrael

Personalised recommendations